Categories: press release

Hemanext appoints LINK Medical Research to run thier second study

LINK Medical contracted by Hemanext to run a study to assess the Hemanext ONE® Red Blood Cell (RBC) Processing and Storage System

Hemanext, inc. appoints LINK Medical Research to run a study to assess the Hemanext ONE® Red Blood Cell (RBC) Processing and Storage System. The study will include patients that receive transfusions of hypoxic RBC units processed with Hemanext ONE, with the purpose of evaluating the safety and efficacy of hypoxic red blood cells processed with the Hemanext ONE system.

LINK Medical Research appointed by Ectin Research AB as CRO for its landmark Phase I/II Study of a new treatment for metastatic bladder cancer

LINK Medical Research appointed by Ectin Research AB as CRO for its landmark Phase I/II Study of a new treatment for metastatic bladder cancer

LINK Medical Research has been appointed by Ectin Research AB as CRO for its landmark Phase I/II Study of a new treatment for metastatic bladder cancer. This is significant news as bladder cancer is one of the most aggressive cancers; 50-70% of tumours recur and 10-20% become metastatic. Current treatments of metastatic bladder cancer require frequent, long hospital visits, have limited efficacy a

Your trusted CRO partner

LINK Medical is a full-service contract research organization (CRO) providing product development services for the pharmaceutical and medical device industries across Northern Europe. We offer a well-integrated local presence in the Nordics, UK, and Germany. Reaching from early phase development to post-marketing, we provide expert guidance across every aspect of a project – all from ONE source.

LINK Medical

Gjerdrums vei 19
NO-0484 Oslo
Norway